Abstract
Background
The follow-up of patients with cutaneous melanoma is controversial. Current recommendations suggest routine history and physical examination every 3 to 6 months for the first 3 years and correlate studies including laboratory tests and radiographic imaging. However, the utility of these recommendations are unclear. The purpose of this study was to determine the impact of routine imaging on the method of detection of first recurrence in patients with stage II and sentinel lymph node–positive stage III melanoma.
Methods
We analyzed a prospective database of all cutaneous melanoma patients treated at our institution from 1997 to 2005 who had at least 2 years of follow-up. The method of detection of initial recurrence was analyzed.
Results
One hundred eighteen patients with stage II (n = 83) or III (n = 35) melanoma who were followed for at least 2 years were identified. Forty-three of these patients developed recurrence (median time to recurrence, 14 months). Site of first recurrence was as follows: 4 local, 17 in transit, 7 regional lymph node, and 15 distant. Twenty-nine recurrences (67%) were either patient detected or symptomatic. Eleven (26%) were detected by the physician at routine follow-up. Only three (7%) were identified by imaging (two chest X-ray and one brain magnetic resonance imaging) in an otherwise asymptomatic patient.
Conclusions
Two-thirds of all initial recurrences of cutaneous melanoma were either detected by a patient or were symptomatic, with most of the remainder detected during routine physical examination. Routine imaging added little value in the detection of initial recurrence.
Similar content being viewed by others
References
Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance. Patient or physician based? Ann Surg. 1995;221:566–9.
Poo-Hwu WJ, Ariyan S, Lamb L, et al. Follow-up recommendations for patients with American Joint Committee on Cancer stages I–III malignant melanoma. Cancer. 1999;86:2252–8.
Garbe C, Paul A, Kohler-Spath H, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21:520–9.
Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005;6:608–21.
Francken AB, Shaw HM, Accortt NA, et al. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol. 2007;14:1924–33.
Nieweg OE, Kroon BB. The conundrum of follow-up: should it be abandoned? Surg Oncol Clin N Am. 2006;15:319–30.
Weiss M, Loprinzi CL, Creagan ET, et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA. 1995;274:1703–5.
Dicker TJ, Kavanagh GM, Herd RM, et al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol. 1999;140:249–54.
Cutaneous malignant melanoma. ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2007;18(Suppl 2):ii71–3.
Hofmann U, Szedlak M, Rittgen W, et al. Primary staging and follow-up in melanoma patients—monocenter evaluation of methods, costs and patient survival. Br J Cancer. 2002;87:151–7.
National Comprehensive Cancer Network. Melanoma: clinical practice guidelines in oncology. Available at: http://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf. Accessed March 7, 2008.
Swetter SM, Carroll LA, Johnson DL, et al. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol. 2002;9:646–53.
Friedman KP, Wahl RL. Clinical use of positron emission tomography in the management of cutaneous melanoma. Semin Nucl Med. 2004;34:242–53.
Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004;22:4357–68.
Reinhardt MJ, Joe AY, Jaeger U, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol. 2008;24:1178–87.
Clark PB, Soo V, Kraas J, et al. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg. 2006;141:284–8.
Yancovitz M, Finelt N, Warycha MA, et al. Role of radiologic imaging at the time of initial diagnosis of stage T1b–T3b melanoma. Cancer. 2007;110:1107–14.
Centers for Medicare and Medicaid Services. Available at: http://www.cms.hhs.gov/PFSlookup/. Accessed September 22, 2008.
Francken AB, Accortt NA, Shaw HM, et al. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol. 2008. DOI:10.1245/s10434-007-9717-9
Fusi S, Ariyan S, Sternlicht A. Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg. 1993;91:94–8.
Francken AB, Thompson JF, Bastiaannet E, et al. Detection of the first recurrence in patients with melanoma: three quarters by the patient, one quarter during outpatient follow-up. Ned Tijdschr Geneeskd. 2008;152:557–62.
Buzzell RA, Zitelli JA. Favorable prognostic factors in recurrent and metastatic melanoma. J Am Acad Dermatol. 1996;34(5 Pt 1):798–803.
Ollila DW. Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncol. 2006;7:919–24.
Phan GQ, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin–2 in patients with metastatic melanoma. J Clin Oncol. 2001;19:3477–82.
Kaufmann R, Spieth K, Leiter U, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol. 2005;23:9001–7.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Meyers, M.O., Yeh, J.J., Frank, J. et al. Method of Detection of Initial Recurrence of Stage II/III Cutaneous Melanoma: Analysis of the Utility of Follow-Up Staging. Ann Surg Oncol 16, 941–947 (2009). https://doi.org/10.1245/s10434-008-0238-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-008-0238-y